- Conditions
- Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Interventions
- Aldesleukin, Laboratory Biomarker Analysis, Ziv-Aflibercept
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 17 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 21
- States / cities
- Duarte, California • Sacramento, California • South Pasadena, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Trauma Exposure, Trauma, Trauma and Stressor Related Disorder, Mental Health Functioning, Chronic Medical Conditions, Chronic Medical Condition, Chronic Medical Illness, Posttraumatic Stress Disorder PTSD, Posttraumatic Stress Disorders, Posttraumatic Stress Symptoms, Posttraumatic Stress
- Interventions
- Structured Psychotherapy for Adolescents Responding to Chronic Stress - Group, Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents - Group, Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents - Individual, Structured Psychotherapy for Adolescents Responding to Chronic Stress - Individual
- Behavioral
- Lead sponsor
- Anthony Vesco
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Bipolar I Disorder, Depression
- Interventions
- Cariprazine, Aripiprazole/Escitalopram combination, Quetiapine, Lurasidone
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2,726 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Bloomington, Indiana • Baltimore, Maryland + 13 more
- Conditions
- Mantle Cell Lymphoma, Untreated
- Interventions
- Lenalidomide, R-CHOP, high-dose cytarabine (HIDAC)
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Anxiety Disorders
- Interventions
- Fluoxetine, Cognitive Behavioral Therapy (CBT)
- Drug · Behavioral
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer
- Interventions
- Durvalumab, Tremelimumab, Olaparib Pill, Thoracic Radiotherapy
- Drug · Radiation
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Autologous Hematopoietic Stem Cell Transplant
- Interventions
- RS-4i Plus Sequential Stimulator (RS Medical, Vancouver, WA)
- Device
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Metastatic Ewing Sarcoma
- Interventions
- Vincristine, Doxorubicin, Cyclophosphamide, Ifosfamide, Actinomycin, Irinotecan, Cabozantinib, Topotecan, Temozolomide, Etoposide, Liposomal doxorubicin
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Hartford, Connecticut + 16 more
- Conditions
- Urinary Bladder Cancer, Upper Tract Urothelial Cancer, Urothelial Cancer
- Interventions
- Sequential Gemcitabine and Jelmyto Treatment (Gem/Jel)
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Suicide, Suicidal Ideation
- Interventions
- Brief Cognitive Behavioral Therapy (BCBT), Treatment As Usual (TAU)
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Colorado Springs, Colorado
- Conditions
- Multiple Myeloma
- Interventions
- Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance, AHCT intensification, Dara-R consolidation, Dara-R maintenance, Dara-VRd induction
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Denver, Colorado • New York, New York + 7 more
- Conditions
- Multiple Myeloma
- Interventions
- carfilzomib, Dexamethasone, Clarithromycin, Lenalidomide
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Osteoarthritis, Knee
- Interventions
- Usual PT Care (UC), BOOST-OA
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Obesity
- Interventions
- Sequential BT, Standard BT
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Suicide, Attempted, Suicidal Ideation
- Interventions
- Brief Cognitive Behavioral Therapy (BCBT), Present-Centered Therapy (PCT), Treatment as Usual (TAU)
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 3
- States / cities
- Jacksonville, North Carolina • Columbus, Ohio • Charleston, South Carolina
- Conditions
- Metastatic Melanoma
- Interventions
- Aldesleukin: All Patients, Nivolumab: Cohort 1 (Cutaneous), Nivolumab: Cohort 2 (Ocular), Ipilimumab: Cohort 2 (Ocular)
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Burnsville, Minnesota
- Conditions
- Food Hypersensitivity, Milk Hypersensitivity
- Interventions
- Baked Milk, Non-baked Milk
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 4 Years to 10 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Leukemia
- Interventions
- aldesleukin, recombinant interferon alfa, sargramostim, busulfan, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Seattle, Washington
- Conditions
- Treatment of Type I Diabetes Mellitus.
- Interventions
- Biological
- Biological
- Lead sponsor
- DiaVacs, Inc.
- Industry
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm, Neurotoxicity
- Interventions
- bortezomib, dexamethasone, melphalan, thalidomide, cytogenetic analysis, fluorescence in situ hybridization, laboratory biomarker analysis, questionnaire administration, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Drug · Genetic · Other + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Lymphedema
- Interventions
- Flexitouch System, Hydroven FPR
- Device
- Lead sponsor
- Tactile Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Chicago, Illinois • Springfield, Illinois + 7 more
- Conditions
- Obesity, Pregnancy Related
- Interventions
- HABITpreg, HABITpost
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 14 Years and older · Female only
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Rheumatoid Arthritis
- Interventions
- IFS, Education
- Behavioral · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 81 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS), High-Grade Papillary Bladder Tumors, BCG-Unresponsive Bladder Cancer, Ta Stage Bladder Cancer, T1 Stage Bladder Cancer, BCG-Refractory Bladder Cancer, High-Risk NMIBC, Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)
- Interventions
- Intravesical Gemcitabine and Docetaxel
- Drug
- Lead sponsor
- Michael A. O'Donnell
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa